Pharmacokinetics of a Novel HIV-1 Protease Inhibitor Incorporated into Biodegradable or Enteric Nanoparticles following Intravenous and Oral Administration to Mice
- 1 December 1995
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 84 (12), 1387-1391
- https://doi.org/10.1002/jps.2600841202
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Controlled-release coevaporates of dipyridamole prepared with acrylic polymersInternational Journal of Pharmaceutics, 1994
- Distribution, kinetics and elimination of radioactivity after intravenous and intramuscular injection of 14C-savoxepine loaded poly(D,L-lactic acid) nanospheres to ratsJournal of Controlled Release, 1994
- CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activityAntimicrobial Agents and Chemotherapy, 1993
- HIV‐1 Protease Inhibitors: Development, Status, and Potential Role in the Treatment of AIDSArchiv der Pharmazie, 1993
- Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle sizeInternational Journal of Pharmaceutics, 1992
- Intracellular targeting of antibiotics by means of biodegradable nanoparticlesJournal of Controlled Release, 1992
- Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseAntimicrobial Agents and Chemotherapy, 1991
- Jejunal Absorption, Pharmacological Activity, and Pharmacokinetic Evaluation of Indomethacin-Loaded Poly(d,l-Lactide) and Poly(Isobutyl-Cyanoacrylate) Nanocapsules in RatsPharmaceutical Research, 1991
- Nanocapsules as carriers for oral peptide deliveryJournal of Controlled Release, 1990
- HTLV-III gag Protein Is Processed in Yeast Cells by the Virus pol -ProteaseScience, 1986